Monash University Study: Copper Compound Reduces Alzheimer’s Proteins, Improves Memory in Mice A copper-based drug reduced toxic amyloid-beta proteins by 42 percent and improved spatial learning by nearly 44 percent in a mouse model of Alzheimer’s disease, according to a study published June 15 in ACS Chemical Neuroscience. The compound, Cu(ATSM), restored the blood-brain barrier’s P-glycoprotein (P-gp) pumps, increasing their abundance by 24.1 percent, researchers at Monash University reported. The drug has already undergone safety testing for other neurological conditions, including Parkinson’s disease and ALS, potentially accelerating human trials for Alzheimer’s, the authors stated. Mechanism: Restoring Blood-Brain Barrier Pumps Alzheimer’s…

Newswire

Features

The Latest